News and Events
Are you using the right reagents for Hemophilia testing?
Hemophilia testing is complicated – DiaPharma scientists can help you choose the right assays for your testing needs. We offer a variety of kits and reagents to measure FVIII and FIX. Contact us to learn more.
COAMATIC® FVIII (K822585)
COATEST® SP FVIII (K824086)
COATEST® SP4 FVIII (K824094)
● Contains bovine FIXa + FX reagents
● FDA-cleared
Technochrom FVIII 2G on Ceveron® s100*
● Automated sensitive FVIII assay
Technoclone Factor FVIII Inhibitor (Bethesda)* – fully automated coming soon!
Ceveron® TGA RB on Ceveron® s100*
● Automated, standardized thrombin generation assay
● Optimized for measurement of bleeding tendency, hemophilia research & development
● Explore thrombin generation assay options on the Ceveron s100
● Chromogenic FIX for Hemophilia B research
● Accurate and easy to use
*For research use only in US and Canada. Not for use in diagnostic procedures.
Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
An alternative is the M30 Apoptosense® ELISA*.
What is the M30 Apoptosense® ELISA?
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
-
CHOOSING WISELY – Coagulation Testing Recommendations
Posted: January 25, 2023
David L. McGlasson, MS, MLS(ASCP) Choosing Wisely is a United States-based health educational campaign led by the American Board of Internal Medicine Foundation (ABIMF) and the Consumers’ Union to reduce the prevalence of unnecessary diagnostic tests and treatments.1 The Choosing Wisely campaign goal is to disseminate information for clinicians and patients that provides diagnostic care…
-
A STEEEEP learning curve: My take home messages from an Alcohol-associated Liver Disease meeting from a newbie
Posted: January 3, 2023
– Olivia Stricker, PhD and Commercial Business Development Manager at DiaPharma Group I recently attended the AASLD Emerging Topics in Alcohol-associated Liver Disease conference in Philadelphia, PA. Although I had been researching clinical practices in alcohol-associated liver disease (ALD) for the past 6 months, I quickly realized how limited my perspective was from only consuming…
-
The Debate of Early-Liver Transplantation for Alcohol-associated Liver Diseases
Posted: December 21, 2022
-Contributed by Abi Kasberg, PhD After recently attending the AASLD Emerging Topics in Alcohol-associated Liver Disease conference, it quickly came to my attention the complexities and challenges that are faced while treating alcohol- associated liver diseases (ALD). For one, current treatment options for ALD are incredibly limited. ALD therapies are disputed in effectiveness and can…
-
THSNA 2022 Recap
Posted: October 7, 2022
Chicago, IL, August 15-18, 2022 David L. McGlasson, MS, MLS(ASCP) The recent THSNA 2022 meeting that was held in Chicago, IL from August 15-18, 2022, was a welcome event, as attendees for the first time in a couple of years could attend the conference in person or virtually. Finally, attendees had the ability to…
-
VACCINE-INDUCED THROMBOTIC THROMBOCYTOPENIA (VITT): INSIGHTS FROM ISTH 2022
Posted: September 26, 2022
– Contributed by Abi Kasberg, PhD Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and severe complication of adenoviral-based COVID-19 vaccinations. VITT occurs at a rate of 1:100,000 to 1:1,000,000 and is associated with high morbidity and mortality. Long term complications of VITT and VITT antibodies can persist for more than 9 months and has…
-
Emerging Therapeutic Targets for Hereditary Angioedema
Posted: August 31, 2022
-Contributed by Abi Kasberg, PhD Hereditary Angioedema (HAE) is a rare, inherited, autosomal dominant disorder that is characterized by fluid accumulation and tissue swelling that can be painful and potentially life-threatening. This form of angioedema is driven by vasculature leakage into surrounding tissues including in the hands, feet, lips, genitals, gastrointestinal tract, or airway. Normal…